Analysis of CYP2C9*2, CYP2C19*2, and CYP2D6*4 polymorphisms in patients with type 2 diabetes mellitus

Bosnian Journal of Basic Medical Sciences

Volumn 10, Issue 4, 2010, Pages 287-291

  Semiz, Sabina ^a   Dujic, Tanja ^a   Ostanek, Barbara ^b   Prnjavorac, Besim ^a,c   Bego, Tamer ^a   Malenica, Maja ^a   Marc, Janja ^b   Causevic, Adlija ^a  

^a UNIVERSITY OF SARAJEVO   (Bosnia and Herzegovina)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

^c General Hospital Te anj   (Bosnia and Herzegovina)

Author keywords

Diabetes; Drug metabolising enzymes; Pharmacogenetics

Indexed keywords

CYP2C19 PROTEIN, HUMAN; CYP2C9 PROTEIN, HUMAN; CYTOCHROME P450 2D6; UNSPECIFIC MONOOXYGENASE;

ADULT; ARTICLE; CASE CONTROL STUDY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENETICS; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACOGENETICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; ARYL HYDROCARBON HYDROXYLASES; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP2D6; DIABETES MELLITUS, TYPE 2; FEMALE; GENE FREQUENCY; GENETIC VARIATION; HUMANS; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 78649799516     PISSN: 15128601     EISSN: 18404812     Source Type: Journal    
DOI: 10.17305/bjbms.2010.2662     Document Type: Article

References (15)

1. International Diabetes Federation. Diabetes Atlas, Third edition. 2007. IDF website: http://www.idf.org.
2. Levy RH, Thummel KE, Trager WF, Hansten PD, Eichelbaum M. Metabolic Drug Interactions. London, Lippincott Williams & Wilkins, 2000.
3. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl/Med 2005; 352(21):2211-2221.
4. Lynch T, Price A. The effect of Cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Earn Physician 2007; 76(3):391-396.
5. Bradford LD. CYP2D6 allele frequency in Europen caucasians, Asians, Africans, and their descendants. Pharmacogenomics 2002; 3(2):229-243.
6. Arvanitidis K, Ragia G, Iordanidou M, Kyriaki S, Xanthi A, Tavri-dou A, et al. Genetic polymorphisms of drug-metabolising enzymes CYP2D6, CYP2C9, CYP2C19, and CYP3A5 in the Geek population. Fundament Clin Pharmacol 2007; 21 (4):419-426.
7. Zanger UM, Turpeinen M, Klein K, Schwab M. Functional phar-macogenetics/genomics of human cytochrome P450 involved in drug biotransformation. Anal Bioanal Chem 2008; 392(6):1093-1108.
8. Yamada Y, Matsuo H, Watanabe S, Kato K, Yajima K, Hibino T, et al. Association of a polymorphism of CYP3A4 with type 2 diabetes mellitus. Intern J Mol Med 2007;20(5)703-707.
9. Wang CP, Hung WC, Yu TH, Chiu CA, Lu LF, Chung FM, et al. Genetic variation in the G-50T polymorphism of the cytochrome P450 epoxygenase CYP2J2 gene and the risk of younger onset type 2 diabetes among Chinese population: potential interaction with body mass index and family history. Exp Clin Endocrinol Diabetes 2010; 118(6):346-52.
10. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16(3):12l5.
11. Molokhia M, Bhatia S, Nitsch D. Genetic determinants of statin-induced myopathy. Personalized Medicine 2008; 5(5):481-494.
12. Pearson ER. Pharmacogenetics in diabetes. Curr Diabetes Report 2009;9(2):172-181.
13. Ledl M, Hohenecker J, Francesconi C, Roots I, Bauer MF, Roden M. Acute myopathy in a type 2 diabetic patient on combination therapy with metformin, fenofibrate and rosiglitazone. Diabetolo-gia 2005; 48(10):1996-1998.
14. Willrich MA, Hirata MH, Hirata RD. Statin regulation of CYP3A4 and CYP3A5 expression. Pharmacogenomics 2009; 10(6): 1017-1024.
15. Antons KA, Williams CD, Baker SK, Phillips PS. Clinical perspectives of statin-induced rhabdomyolysis./tm/Med 2006;119(2):400-409.